1D3FBEA0-9A7F-436C-AA71-366D4E11C43B
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 35.446780551905384
- age_years
- 38
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.449
- CHOLESTEROL_HOMEOSTASIS+0.410
- OXIDATIVE_PHOSPHORYLATION+0.316
- MITOTIC_SPINDLE+0.293
- HEME_METABOLISM+0.271
- FATTY_ACID_METABOLISM+0.263
- HEDGEHOG_SIGNALING+0.256
- MTORC1_SIGNALING+0.240
- UNFOLDED_PROTEIN_RESPONSE+0.240
- NOTCH_SIGNALING+0.231
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.487
- IL6_JAK_STAT3_SIGNALING-0.462
- ANGIOGENESIS-0.364
- INTERFERON_GAMMA_RESPONSE-0.359
- TNFA_SIGNALING_VIA_NFKB-0.345
- INFLAMMATORY_RESPONSE-0.307
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.305
- COAGULATION-0.255
- E2F_TARGETS-0.218
- COMPLEMENT-0.217
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1056 | — | — | 0.902 |
| 2 | 3DC38276-A6D2-49C6-8F54-3F50F6BFAD0C | — | — | 0.901 |
| 3 | 1E2D87A6-48B8-47FA-A801-AFEA7E01E829 | — | — | 0.868 |
| 4 | EF7D394C-BAB6-4826-AE09-9E5E884E0023 | — | — | 0.863 |
| 5 | 02F669D8-FB9F-45AF-A999-5886E5C2DAF0 | — | — | 0.862 |
| 6 | D155B4CA-927F-4B4F-B6BC-2D41267F195E | — | — | 0.861 |
| 7 | BB79CABB-0912-4E02-ACD9-82EF3AB8B598 | — | — | 0.841 |
| 8 | BAA2D0D4-DD8C-4F80-8D37-986AFC578536 | — | — | 0.840 |
| 9 | FD166A94-332D-426D-9E36-E4272F3772FC | — | — | 0.839 |
| 10 | SRR934841 | — | — | 0.835 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.449 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.410 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.316 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.293 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.271 | Temsirolimus | — uncovered |
| FATTY_ACID_METABOLISM | 0.263 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.256 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.240 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.231 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.231 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.221 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.202 | Idelalisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.167 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.072 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.035 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.034 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.015 | Inavolisib | — uncovered |